We are live on ! Find out more
SCP

SymBiosis Capital Partners Portfolio holdings

AUM $52.8M
This Fund
S&P 500
This Quarter Est. Return
+15.04%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$52.8M
AUM Growth
-$56.7M
Cap. Flow
-$59.3M
Cap. Flow %
-112.33%
Top 10 Hldgs %
100%
Holding
12
New
1
Increased
–
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$9.77M

Top Sells

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$15.4M
2
AMPG icon
AmpliTech
AMPG
+$13.2M
3
PGEN icon
Precigen
PGEN
+$12.5M
4
NUVB icon
Nuvation Bio
NUVB
+$11.2M
5
AARD
Aardvark Therapeutics
AARD
+$6.26M

Sector Composition

Rank Sector Weight
1 Healthcare 95.97%
2 Consumer Staples 4.03%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVMN
1
Evommune Inc
EVMN
$507M
$29.4M 55.8%
1,280,778
– –
IVA
2
Inventiva
IVA
$1.12B
$13.1M 24.76%
2,354,000
-246,000
-9% -$1.5M
WVE icon
3
Wave Life Sciences
WVE
$1.04B
$5.44M 10.3%
+750,000
New +$9.77M
RANI icon
4
Rani Therapeutics
RANI
$97.6M
$2.69M 5.11%
3,667,585
-2,632,415
-42% -$3.36M
CLNN icon
5
Clene
CLNN
$54.7M
$2.13M 4.03%
431,094
-339,401
-44% -$1.74M
SRZNW
6
DELISTED
Surrozen Inc Warrant
SRZNW
$2.4K ﹤0.01%
150,000
– –
AMPG icon
7
AmpliTech
AMPG
$106M
– –
-2,555,000
Closed -$13.2M
GBIO
8
DELISTED
Generation Bio
GBIO
– –
-665,000
Closed -$3.78M
NUVB icon
9
Nuvation Bio
NUVB
$2.49B
– –
-1,250,000
Closed -$11.2M
PGEN icon
10
Precigen
PGEN
$2.7B
– –
-3,000,000
Closed -$12.5M
VSTM icon
11
Verastem
VSTM
$634M
– –
-2,000,000
Closed -$15.4M
AARD
12
Aardvark Therapeutics
AARD
$144M
– –
-476,595
Closed -$6.26M

Similar funds

HPM
HealthCor Partners Management Charleston, South Carolina $50.7M AUM
IPHI
Inflection Point Holdings II New York $47.3M AUM
RRC
Range Rock Capital Wellesley, Massachusetts $46.7M AUM
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
TCM
Tanaka Capital Management New York $59.9M AUM
GC
Greencape Capital Melbourne, Australia $59.9M AUM 23.92% 1-Year Est. Return
ACM
AREX Capital Management New York $60.5M AUM 45.91% 1-Year Est. Return
SPIG
Silversmith Partners I GP Boston, Massachusetts $39.2M AUM

SymBiosis Capital Partners's Q1 2026 Portfolio in Review

As of Q1 2026, SymBiosis Capital Partners held 12 positions worth $52.8M, down 52% from $109M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

SymBiosis Capital Partners withdrew a net $59.3M in Q1 2026, closing 6 positions and reducing 3 holdings. Its most notable exit was Verastem, an estimated $15.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 84% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, SymBiosis Capital Partners opened a new position in Wave Life Sciences worth $5.44M.

  • SymBiosis Capital Partners's largest Q1 2026 buy was Wave Life Sciences: 750,000 shares worth $5.44M.
  • SymBiosis Capital Partners's biggest Q1 2026 reduction was Rani Therapeutics, cutting an estimated $3.36M.
  • SymBiosis Capital Partners fully exited Verastem in Q1 2026, selling an estimated $15.4M.
  • SymBiosis Capital Partners's ten largest holdings make up 100% of its $52.8M portfolio in Q1 2026.
  • SymBiosis Capital Partners opened 1 new position and closed 6 in Q1 2026.
  • SymBiosis Capital Partners's portfolio value fell 52% quarter-over-quarter to $52.8M.

Based on SymBiosis Capital Partners's 13F filing for Q1 2026, filed 12 May 2026.